Curevo Vaccine announces closing of $26m Series A1 round

Clinical-stage biotechnology company Curevo Vaccine has announced the closing of $26m Series A1 financing round

Curevo Vaccine CEO George Simeon said: “Completing this A1 round ahead of data from our Phase 2b trial of CRV-101 head-to-head against Shingrix is a meaningful demonstration of the confidence our investors have in the CRV-101 programme.